← Back to All Stocks

Acrivon Therapeutics, Inc. (ACRV) Analysis

Generated on: 2025-06-23 13:49:09 UTC
All stock prices are delayed.
Use of this site does not constitute financial advice.
⚠️ VERY LOW FLOAT STOCK - 16,676,349 shares

Analysis Values

Current Price
$1.26
Predicted Price
$1.51
Expected Return
16.32%
Confidence Score
0.82
RSI (14)
59.25
MACD
-0.06
Volume
20,531
Float Shares
16,676,349
Reddit Posts
0
News Items
1
SEC Filings
0
Data Points
250

ACRV

Acrivon Therapeutics, Inc.
16.32%
Price: $1.26
Confidence: 0.82
News
Low Float
Last updated: 2025-06-23 13:49:08

Technical Analysis

RSI: 59.25
MACD: -0.06
Technical Analysis Graph

Risk Analysis

Volatility
108.34%
Max Drawdown
-89.48%
Beta
1.0
Risk Score
99.1

Social Sentiment

0
Social Sentiment Score (0-100)

Recent News

News thumbnail
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
TipRanks - 2025-05-17 16:30
JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to re-validate the company’s tumor-selection platform, the analyst tells investors in a research note. The firm prefers to wait for initial data from ACR-2316 in the second half of 2025 and more meaningful data in 2026 before recommending the shares. Jones would like to see some “real de-risking clinical data to comfortably” value Acrivon’s biomarker-base

Reddit Discussions

No recent Reddit discussions found.

Recent SEC Filings

No recent SEC filings found.